## Judy Wang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9474251/publications.pdf

Version: 2024-02-01

1937685 2272923 4 121 4 4 citations h-index g-index papers 4 4 4 115 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical Cancer Research, 2021, 27, 1864-1874.	7.0	20
2	Reversible HER2 antibody-drug conjugate–induced ocular toxicity. Canadian Journal of Ophthalmology, 2021, , .	0.7	7
3	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical Cancer Research, 2021, 27, 3602-3609.	7.0	20
4	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74